HEALIUS LIMITED — Director's Dealing 2017

Nov 26, 2017

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	PRIMARY HEALTH CARE LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Malcolm Parmenter
Date of last notice	7 September 2017(Appendix 3X)

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to therelevantinterest.	As shown
Date of change	24 November 2017
No. of securities held prior to change	NIL
Class	Fully paid ordinary shares
Number acquired	50,000
Number disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$3.51675 per share
No. of securities held after change	50,000 Ordinary shares Malcolm W Parmenter Pty Ltd atf Malcolm W Parmenter Superannuation Fund
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	On-market trade

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where Not applicable prior written clearance was required? If so, was prior written clearance provided to allow the Not applicable trade to proceed during this period? If prior written clearance was provided, on what date Not applicable was this provided?

Charles Tilley Company Secretary Date: 24 November 2017

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011